LIST OF REFERENCES CITED BY APPLICANT					ATTY. DOCKET NO. APPLICATION NO. 11582-004-999 10/550,482 APPLICANT			
					Li et al.			
					FILING DATE		GROUP ART	UNIT
					October 13, 2006)	1614	
			U.S. PA	TENT DOCUM	1ENTS			
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE			FILING DATE IF APPROPRIATE		
	A01	2,275,354	03/03/1942	Ewins et al.				
	A02	3,819,639	06/27/1974	Delarge et al.	PARICULA - 1400 (1904 (1			
~	A03	2005/0070582 A1	03/31/2005	Li et al.				

	FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	B01	WO 99/55324 A1	11/04/1999				
	B02	WO 00/42003 A1	07/20/2000				
	B03	WO 00/76513 A1	12/21/2000				
	B04	WO 00/76514 A1	12/21/2000	COMMANDE A COMMAND AND A COMMA			
	B05	WO 01/32604 A1	05/10/2001	W. W			
	B06	WO 03/022277 A1	03/20/2003				

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
C01	Alaaeddine et al., "Production of the Chemokine RANTES by Articular Chrondrocytes and Role in Cartilage Degradation," Arthritis & Rheumatism, Vol. 44, No. 7, pp. 1633-43 (2001)
C02	
C03	Aust et al., "Grave's disease is associated with an altered CXCR3 and CCR5 expression in thyroid-derived compared to peripheral blood lymphocytes," Clin. Exp. Immunol., Vol. 127, pp. 479-485 (2001)
C04	Bhattacharya, et al., "Increased expression of eotaxin-3 distinguishes between eosinophilic esophagitis and gastroesophageal reflux disease," <i>Human Pathology</i> , Vol. 38, pp. 1744-53 (2007)
C05	Blanchard <i>et al.</i> , "Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis," <i>J. Clin. Invest.</i> , Vol. 116, No. 2, pp. 536-47 (2006)
C06	Bullock et al. "Interplay of adaptive Th2 immunity with eotaxin-3/C-C chemokine receptor 3 in eosinophilic esophagitis," J. Pediatric Gastroenterology and Nutrition, Vol. 45, pp. 22-31 (2007)
C07	Cheadle <i>et al.</i> , "Eotaxin-2 and colorectal cancer: a potential target for immune therapy," <i>Human Cancer Biol.</i> , Vol. 13, No. 19, pp. 5719-28 (2007)
C08	CHEMCATS Database, Ambinter Stock Screening Collection, Order Nos. 7J-012, 7J-005 and 7J-004.
C09	"Chemokine CCR3 Antagonists," Exp. Opin. Ther. Patents, 2000, 10(9): 1455-1459.
C10	Chi et al., "C-Reactive protein enhances expression of chemokine receptors on mast cells," <i>The FASEB Journal</i> Vol. 16, No. 4, p. A690, abstract 514.2
C11	Delarge, J., "Nouveaux Anti-inflammatoires Derives de la Pyridine," <i>Ann. Pharm. Fr.</i> , 1973, Vol. 31, No. 6, pp. 467-474. (English summary at p. 474).
C12	Dol <i>et al.</i> , "Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice," <i>J. Cardiovascular Pharmacology</i> , Vol. 38, pp. 395-405 (2001)
C13	Elsner et al., "Human Eotaxin Represents a Potential Activator of the Respiratory Burst of Human Eosinophils," Eur. J. Immunol., Vol. 26, pp. 1919-25 (1996).
C14	Foster <i>et al.</i> , "Elemental signals regulating eosinophil accumulation in the lung," <i>Immunol. Rev.</i> , Vol. 179, pp. 173-181 (2001)
C15	Gerber et al., "Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with

	of Application No. 10/550,482
	eosinophils," Current Biology, Vol. 7, pp. 836-43 (1997)
C16	Haley et al., "Overexpression of Eotaxin and the CCR3 Receptor in Human Atherosclerosis: Using Genomic Technology to Idenify a Potential Novel Pathway of Vascular Inflammation," Circulation, Vol. 102, pp. 2185-89 (2000)
C17	
C18	
C19	
C20	
C21	
C22	2004/084898.
C23	relationship with eosophil cationic protein and lung function," Mediators of Inflam., Vol. 9, pp. 175-79 (2000)
C24	Johrer et al., "Up-regulation of functional chemokine receptor CCR3 in human renal cell carcinoma," <i>Human Cancer Biol.</i> , Vol. 11, No. 7, pp. 2459-65 (2005)
C25	pp. 2702-08 (2005)
C26	Synovial Tissue Monocytes/Macrophages in Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , Vol. 44, No. 5, pp. 1022-32 (2001)
C27	that promotes cell growth," J. Neuro-Oncology, Vol. 70, pp. 301-07 (2004)
C28	Lamkhioued <i>et al.</i> , "Increased expression of eotaxin in bronchoaveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation," <i>J. Immunol.</i> , Vol. 159, pp. 4593-4601 (1997)
C29	Li et al., "Mast Cells/Basophils in the Peripheral Blood of Allergic Individuals Who Are HIV-1 Susceptible Due to Their Surface Expression of CD4 and the Chemokine Receptors CCR3, CCR5 and CXCR4," <i>Blood</i> , Vol. 97, No. 11, pp. 3484-87 (2001)
C30	32 (2001)
C31	(2001)
C32	Tetrahedron, 1963, Vol. 19, pp. 357-372.
C33	Am. J. Respir. Cell and Mol. Biol., Vol. 18, pp. 255-64 (1998)
C34	cells and monocytes in rheumatoid arthritis," <i>J. Rheumatol.</i> , Vol. 30, No. 9, pp. 1928-34 (2003)
C35	derived from brain and blood or patients with AIDS," J. Virology, Vol. 77, No. 22, pp. 12336-12345 (2003)
C36	CCL22) and express chemokine receptors," <i>Inflamm. Res.</i> , Vol. 50, pp. 168-174 (2001)
C37	Park et al., "CD4 Receptor-Dependent Entry of Human Immunodeficiency Virus Type-1 env-Pseudotypes into CCR5-, CCR3- and CXCR4-Expressing Human Alveolar Macrophages Is Preferrentially Mediated by the CCR5 Coreceptor," Am. J. Respir. Cell Mol. Biol., Vol. 20, pp.864-871 (1999)
C38	
C39	
C40	
C41	Sabroe et al., J. Immunol., "Cloning and Characterization of the Guinea Pig Eosinophil Eotaxin Receptor, C-C Chemokine Receptor-3: Blockade Using a Monoclonal Antibody In Vivo," Vol. 161, pp. 6139-47 (1998)
C42	Sallusto <i>et al.</i> , "Selective Expression of the Eotaxin Receptor CCR3 by Human T Helper 2 Cells," <i>Science</i> , Vol. 277, pp. 2005-2007 (1997)
C43	Saito <i>et al.</i> , "Selective regulation of chemokine production in human epithelial cells," <i>J. Infect. Dis.</i> , Vol. 175, pp. 479-504 (1997)

 	of Application 146, 10/330,482
C44	Silva et al., "Differential expression of chemokines and chemokine receptors in inflammatory periapical
	diseases," Oral Microbiol. Immunol., Vol. 20, pp. 310-16 (2005)
C45	Simchen et al. "Expression and Regulation of Regulated on Activation, Normal T Cells Expressed and Secreted
	in Thyroid Tissue of Patients with Graves' Disease and Thyroid Autonomy and in Thyroid-Derived Cell
	Populations," J. Clinical Endocrinology & Metabolism, Vol. 85, No. 2, 4758-64 (2000)
C46	Stellato et al., "Cutting Edge: Expression of the C-C Chemokine Receptor CCR3 in Human Airway Epithelial
	Cells," J. Immunology, 1457-60 (2001)
C47	Sugasawa et al., "Prognostic significance of expression of CCL5/RANTES receptors in patients with gastric
	cancer," J. Sergical Oncology, Vol. 97, pp. 445-50 (2008)
C48	Teixeira et al., "Increased serum levels of CCL11/eotaxin in schizophrenia," Progress in Neuro-pharmacology
	& Biol. Psych., Vol. 32, pp. 710-14 (2008)
C49	Uguccioni et al., "High Expression of the Chemokine Receptor CCR3 in Human Blood Basophils," J. Clin.
	Invest., Vol. 100, pp. 1137-43 (1997)
C50	Weeraratna et al., "Alterations in immunological and neurological gene expression patterns in Alzheimer's
	disease tissues," Exp. Cell. Res., Vol. 313, pp. 450-61 (2007)
C51	White et al., "Identification of potent, selective, non-peptide CC chemokine receptor-3 antagonist that inhibits
	eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration," J. Bio. Chem., Vol.
	275, No. 47, pp. 36626-31 (2000)
C52	Xia et al., "Immunihistochemical Study of the β-Chemokine Receptors of CCR3 and CCR5 and Their Ligands
	in Normal and Alzheimer's Diseases Brains," Am. J. Pathology, Vol. 153, No. 1, pp. 31-36 (1998)
C53	Xia et al., "Chemokines/Chemokine Receptors in the Central Nervous System and Alzheimer's Disease," J.
	Neurovirology, Vol. 5, pp. 32-41 (1999)
C54	Xia et al., "Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand
	IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease," J. Immunol., 108, 227-
	35 (2000)
C55	Ying et al., "Enchanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with
	airway hyperresponsiveness and predominant colocalization of eotaxin mRNA to bronchial epithelial and
	endothelial cells," Eur. J. Immunol. Vol. 27, 3507-3516 (1997)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformar considered. Include copy of this form with next communication to applicant.	nce with MPEP 609; Draw line through citation if not in conformance and not